Circulating adipocyte fatty acid-binding protein is a predictor of cardiovascular events in patients with stable angina undergoing percutaneous coronary intervention.
Circulating adipocyte fatty acid-binding protein is a predictor of cardiovascular events in patients with stable angina undergoing percutaneous coronary intervention.
复制标题
DOI：
10.1186/s12872-017-0691-2
复制
发表时间：
2017-10-10
影响因子：
2.1
通讯作者：
Ito H
中科院分区：
文献类型：
--
作者：
Takagi W;Miyoshi T;Doi M;Okawa K;Nosaka K;Nishibe T;Matsuo N;Hirohata S;Ito H
脂肪细胞脂肪酸结合蛋白（A-FABP）在脂肪细胞和巨噬细胞中均有表达。最近的研究表明，A-FABP由脂肪细胞分泌，其浓度与肥胖、胰岛素抵抗和动脉粥样硬化有关。我们已经报道了冠状动脉粥样硬化负荷与血清A-FABP浓度有关。在本研究中，我们研究了经皮冠状动脉介入治疗（PCI）的稳定型心绞痛患者血清A-FABP浓度是否与预后相关。这是一项前瞻性单中心试验。2008年8月至2010年7月，共有130名稳定型心绞痛患者在香川县中心医院接受了首次PCI治疗。主要终点为心血管死亡、非致死性心肌梗死、非致死性卒中、血运重建术和心力衰竭住院。在随访期间（中位50个月；四分位数范围23-66个月），发生49例心血管事件。Kaplan-Meier分析显示，高A-FABP组（A-FABP中位浓度≥18.6 ng/ml）的主要终点累积发生率高于低A-FABP组。Cox分析显示，经年龄和多血管疾病校正后，A-FABP浓度是心血管事件的独立预测因子（风险比为1.03；95%可信区间为1.01-1.04;p = 0.01）。稳定型心绞痛PCI患者血清A-FABP浓度与预后相关，提示血清A-FABP浓度可用于二级预防的风险评估。UMIN临床试验注册表UMIN000029283（注册日期：2017年9月25日），回顾性注册。
Adipocyte fatty acid-binding protein (A-FABP) is expressed in both adipocytes and macrophages. Recent studies have shown that A-FABP is secreted by adipocytes and that the A-FABP concentration is associated with obesity, insulin resistance, and atherosclerosis. We have reported that the coronary atherosclerotic burden is associated with the serum A-FABP concentration. In the present study, we investigated whether the serum A-FABP concentration is associated with prognosis in patients with stable angina pectoris who have undergone percutaneous coronary intervention (PCI). This was a prospective single-center trial. In total, 130 patients with stable angina pectoris undergoing their first PCI were enrolled from August 2008 to July 2010 at Kagawa Prefectural Central Hospital. The primary endpoints were cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, revascularization, and hospitalization for heart failure. During the follow-up (median, 50 months; interquartile range, 23–66 months), 49 cardiovascular events occurred. Kaplan–Meier analysis showed that the cumulative incidence of the primary endpoints in the high A-FABP group (median A-FABP concentration of ≥ 18.6 ng/ml) was greater than that in the low A-FABP group. Cox analysis showed that the A-FABP concentration was an independent predictor of cardiovascular events adjusted for age and the presence of multi-vessel disease (hazard ratio, 1.03; 95% confidence interval, 1.01–1.04; p = 0.01). The serum A-FABP concentration is associated with prognosis in patients with stable angina undergoing PCI, suggesting that the serum A-FABP concentration could be useful for risk assessment of secondary prevention. UMIN Clinical Trials Registry UMIN000029283 (registration date: September 25, 2017), retrospectively registered.
登录
查看更多内容
影响因子：
3.7
作者：
Furuhashi M;Matsumoto M;Hiramitsu S;Omori A;Tanaka M;Moniwa N;Yoshida H;Ishii J;Miura T
通讯作者：
Miura T
血清脂肪酸结合蛋白 4 是终末期肾病心血管事件的预测因子。
影响因子：
3.7
作者：
Furuhashi M;Ishimura S;Ota H;Hayashi M;Nishitani T;Tanaka M;Yoshida H;Shimamoto K;Hotamisligil GS;Miura T
通讯作者：
Miura T
FABP4 通过 MAPK 依赖性途径诱导血管平滑肌细胞增殖和迁移。
影响因子：
3.7
作者：
Girona J;Rosales R;Plana N;Saavedra P;Masana L;Vallvé JC
通讯作者：
Vallvé JC
影响因子：
24
作者：
Fihn, Stephan D.;Gardin, Julius M.;Yancy, Clyde W.
通讯作者：
Yancy, Clyde W.
影响因子：
9.3
作者：
Aragonès G;Saavedra P;Heras M;Cabré A;Girona J;Masana L
通讯作者：
Masana L